← Leaderboards
Lisa A Jackson
Kaiser Foundation Research Institute
$41,789,727
Attributed
$41,789,727
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10.1M · FY2009–25$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,219,797 · 3
CDC$1,569,930 · 1
By mechanism
UM1$24,276,772 · 1
N01$15,943,025 · 2
U01$1,569,930 · 1
Top collaborators
No co-investigators on record.
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Ousseny Zerbo$2,829,715
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationVaccinesConduct Clinical TrialsContractsResourcesDesignClinical TrialsVaccine CandidateNamed GroupRouteInfectious Disease TreatmentInvestigationVaccine TrialInfluenza Virus VaccineMalaria VaccinesNational Institute Of Allergy And Infectious DiseaseClinical Research SiteWashingtonUnited States National Institutes Of HealthInfluenzaProgramsProtocols DocumentationNovel VaccinesCommunicable Diseases
Grant awards (47)
Kaiser Washington Vaccine and Treatment Evaluation Unit$665,827
UM1 · FY2025 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$61,660
UM1 · FY2024 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$628,365
UM1 · FY2023 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$2,248,353
UM1 · FY2022 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit â DMID 21-0004$2,114,527
UM1 · FY2022 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$663,266
UM1 · FY2022 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$314,872
UM1 · FY2022 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$243,453
UM1 · FY2022 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$204,442
UM1 · FY2022 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$82,895
UM1 · FY2022 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012$2,014,564
UM1 · FY2021 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$1,896,679
UM1 · FY2021 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$1,164,520
UM1 · FY2021 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$1,117,166
UM1 · FY2021 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$415,583
UM1 · FY2021 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$337,461
UM1 · FY2021 · AI · contact PI
Kaiser Washington VTEU supplement 20-0003$7,505,188
UM1 · FY2020 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$1,884,389
UM1 · FY2020 · AI · contact PI
Kaiser Washington Vaccine and Treatment Evaluation Unit$713,562
UM1 · FY2020 · AI · contact PI
Vaccine and Treatment Evaluation Unit: Phase I Malaria Vaccine Study$3,218,382
N01 · FY2017 · AI · contact PI
VTEU: Phase I Malaria Vaccine Study$138,132
N01 · FY2016 · AI · contact PI
Vaccine and Treatment Evaluation Unit$375,778
N01 · FY2015 · AI · contact PI
Phase I Malaria Vaccine Study - VTEU$137,248
N01 · FY2015 · AI · contact PI
Vaccine and Treatment Evaluation Units$104,980
N01 · FY2015 · AI · contact PI
Phase II Trial of H7N9 Influenza Vaccines - VTEU$435,112
N01 · FY2014 · AI · contact PI
Vaccine and Treatment Evaluation Units$411,019
N01 · FY2014 · AI · contact PI
Vaccine and Treatment Evaluation Units$383,846
N01 · FY2014 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$379,243
N01 · FY2014 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,000
N01 · FY2014 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$52,453
N01 · FY2014 · AI · contact PI
Vaccine and Treatment Evaluation Units$744,662
N01 · FY2013 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,000
N01 · FY2013 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$50,000
N01 · FY2013 · AI · contact PI
Core_Prospective population-based estimation of influenza vaccine effectiveness a$784,950
U01 · FY2012 · IP · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$600,000
N01 · FY2012 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$500,000
N01 · FY2012 · AI · contact PI
Vaccine and Treatment Evaluation Units$500,000
N01 · FY2012 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,000
N01 · FY2012 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$2,000,000
N01 · FY2011 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$1,000,000
N01 · FY2011 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$1,000,000
N01 · FY2011 · AI · contact PI
Core_Prospective population-based estimation of influenza vaccine effectiveness a$784,980
U01 · FY2011 · IP · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$712,157
N01 · FY2011 · AI · contact PI
VACCINE AND TREATMENT EVALUATION UNITS$500,000
N01 · FY2011 · AI · contact PI
Vaccine and Treatment Evaluation Units$500,000
N01 · FY2011 · AI · contact PI
Vaccine and Treatment Evaluation Units$300,013
N01 · FY2011 · AI · contact PI
Vaccine and Treatment Evaluation Units$1,000,000
N01 · FY2009 · AI · contact PI